Corgard (nadolol) dosing, indications, interactions, adverse effects, and more , , , Corgard (nadolol) dosing, indications, interactions, adverse effects, and more, , , , , , , , , , , , , , , , , Edition:EnglishFrançaisDeutsch, Search, , No Results, News & Perspective, Drugs & Diseases, CME & Education, Log In, Register, , , , , https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cDovL3JlZmVyZW5jZS5tZWRzY2FwZS5jb20vZHJ1Zy9jb3JnYXJkLW5hZG9sb2wtMzQyMzYx, , , processing.... , , , , , nadolol (Rx)Brand and Other Names:Corgard, Classes: Beta-Blockers, Nonselective, , Dosing & Uses, Interactions, Adverse Effects, Warnings, Pregnancy, Pharmacology, Images, Patient Handout, Formulary, Dosing & Uses, AdultPediatricGeriatric, Dosage Forms & Strengths, , tablet, , 20mg, , 40mg, , 80mg, , , more... Hypertension, , 40-320 mg PO qDay, , Angina Pectoris, , Initial 40 mg/day PO, increase gradually q 3-7Days, , Doses up to 160-240mg qDay may be needed, , SVT, Maintenance (Off-label), , 60-160 mg/day PO, , Aggressive Behavior; Upper GI Rebleed (Off-label), , 40-160 mg/day PO, , Migraine, Prophylaxis (Off-label), , 40-80 mg PO qDay (up to 240 mg/day), , Renal Impairment, , CrCl >50 mL/min: Give qDay, , CrCl 31-50 mL/min: Give q24-36hr, , CrCl 10-30 mL/min: Give q24-48hr, , CrCl <10 mL/min: Give q40-60hr, , Hepatic Impairment, , Dose adjustments not necessary, , Additional Information, , Less effective than thiazide diuretics in black and geriatric patients, , Shown to decrease mortality in hypertension and post-myocardial infarction, , Other Indications & Uses, , Off-label: Arrhythmias, GI bleed, hyperthyroidism, reduce IOP, SVT, , Not approved, Hypertension, , 20-320 mg PO qDay, , Angina Pectoris, , Initial 20 mg/day PO, increase gradually q 3-7Days, , Doses up to 160-240mg qDay may be needed, , Interactions, Interaction Checker, nadolol and , No Results, No Interactions Found, Interactions Found, Contraindicated, Serious - Use Alternative, Significant - Monitor Closely, Minor, Sort by : , , Adverse Effects, , >10%, , Drowsiness, , Insomnia, , Decreased sexual ability, , , 1-10%, , Bradycardia (2%) , , Dizziness (2%), , Fatigue (2%), , Hypotension (1%), , , <1%, , Abdominal discomfort, , Constipation, , Diarrhea, , Nausea, , Cough, , Nasal congestion, , , Frequency Not Defined, , Bronchospasm, depression, decreased exercise tolerance, Raynaud's phenomenon , , May increase triglyceride levels and insulin resistance, and decrease HDL levels , , , Warnings, , Black Box Warnings, , May exacerbate ischemic heart disease following abrupt withdrawal, , Hypersensitivity to catecholamines has been observed during withdrawal, , Exacerbation of angina and, in some cases, myocardial infarction occurrence after abrupt discontinuation , , When discontinuing chronically administered beta-blockers (particularly with ischemic heart disease) gradually reduce dose over 1-2 wk and carefully monitor, , If angina markedly worsens or acute coronary insufficiency develops, reinstate beta-blocker administration promptly, at least temporarily (in addition to other measures appropriate for unstable angina), , Warn patients against interruption or discontinuation of beta-blocker without physician advice, , Because coronary artery disease is common and may be unrecognized, slowly discontinue beta-blocker therapy, even in patients treated only for hypertension, , , Contraindications, , Hypersensitivity, , Overt cardiac failure, 2°/3° heart block, cardiogenic shock, , Asthma/COPD, , Avoid during breastfeeding, , Sinus bradycardia, , Sick sinus syndrome without permanent pacemaker, , , Cautions, , Anesthesia/surgery (myocardial depression); chronically administered beta-blocking therapy should not be routinely withdrawn prior to major surgery, however the impaired ability of the heart to respond to reflex adrenergic stimuli may augment the risks of general anesthesia and surgical procedures, , Nonallergenic bronchospasm, cerebrovascular insufficiency, well-compensated CHF, DM, hyperthyroidism/thyrotoxicosis, liver disease, renal impairment, peripheral vascular disease, , Sudden discontinuation can exacerbate angina and lead to myocardial infarction, , Increased risk of stroke after surgery, , Use in pheochromocytoma, , , Pregnancy & Lactation, , Pregnancy Category: C, , Lactation: concentrated in breast milk, use caution (AAP Committee states compatible w/ nursing) , , Pregnancy Categories, A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk. B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA:Information not available. more... Pharmacology, , Mechanism of Action, , Blocks response to beta-adrenergic stimulation to beta1 and beta2 receptors; may reduce portal pressure through beta2 receptor, which reduces portal blood flow , , , Pharmacokinetics, , Half-Life: 10-24 hr, , Onset: 3-4 hr, , Duration: 17-24 hr, , Vd: 1.9 L/kg (1.88-2.02 L/kg), , Peak Plasma Time: 2-4 hr, , Bioavailability: 20-40%, , Protein Bound: 28-30%, , Metabolism: None, , Excretion: Urine, , Dialyzable: Yes (HD), , , Images, , Patient Handout, Print w/ Office Info, Print w/out Office Info, , Formulary, FormularyPatient Discounts, To view formulary information first create a list of plans. Your list will be saved and can be edited at any time. Create Your List of Plans, Adding plans allows you to:, View the formulary and any restrictions for each plan. Manage and view all your plans together – even plans in different states. Compare formulary status to other drugs in the same class. Access your plan list on any device – mobile or desktop. The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information. View explanations for tiers and restrictions, Tier, Description, 1, This drug is available at the lowest co-pay. Most commonly, these are generic drugs. 2, This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs. 3, This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs. 4, This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products. 5, This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products. 6, This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products. NC, NOT COVERED, – Drugs that are not covered by the plan. Code, Definition, PA, Prior Authorization, Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription. , QL, Quantity Limits, Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered. , ST, Step Therapy, Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription. , OR, Other Restrictions, Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription. , Done, Add or Remove Plans, Plans for , Select State: , Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, , Puerto Rico, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming, Non-Medicare PlansMedicare Plans, Select a box to add or remove a plan. close, Select a class to view formulary status for similar drugs, CLOSE, Additional Offers, CLOSE, Email to Patient, From:, To:, The recipient will receive more details and instructions to access this offer. By clicking send, you acknowledge that you have permission to email the recipient with this information. Send, CLOSE, Email Forms to Patient, From:,